Cargando…
ImmunoStart: preparing patients for immunosuppression
OBJECTIVES: Patients with immune-mediated inflammatory disease (IMID) present an increased risk of infection. Here, we present the concept of a preventive consultation called ImmunoStart and the first results of its implementation in the care pathway of patients with IMID. METHODS: Relevant informat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665374/ https://www.ncbi.nlm.nih.gov/pubmed/34909567 http://dx.doi.org/10.1093/rap/rkab092 |
_version_ | 1784613995255169024 |
---|---|
author | Martin, Charlotte Muls, Vinciane Brasseur, Céline Meric de Bellefon, Laurent Lam Hoai, Xuan-Lan Vanderhilst, Jeroen Delforge, Marc Di Romana, Silvana |
author_facet | Martin, Charlotte Muls, Vinciane Brasseur, Céline Meric de Bellefon, Laurent Lam Hoai, Xuan-Lan Vanderhilst, Jeroen Delforge, Marc Di Romana, Silvana |
author_sort | Martin, Charlotte |
collection | PubMed |
description | OBJECTIVES: Patients with immune-mediated inflammatory disease (IMID) present an increased risk of infection. Here, we present the concept of a preventive consultation called ImmunoStart and the first results of its implementation in the care pathway of patients with IMID. METHODS: Relevant information about vaccination history, tuberculosis exposure and other infectious risks were collected through blood sampling, complete anamnesis, chest X-ray and Mantoux test. During the ImmunoStart consultation, vaccination schedules, specific treatments and risk considerations were discussed. RESULTS: Between October 2016 and February 2020, 437 patients were seen at an ImmunoStart consultation, mainly referred by rheumatologists (56%), dermatologists (25%) and gastroenterologists (18%). A total of 421 (96%) patients needed at least one vaccine (a mean of 3.3 vaccines per patient). Live attenuated vaccine was indicated for 45 patients (10%), requiring them to reduce or interrupt their immunosuppressive drug(s). Ninety-two patients (21%) were treated for latent tuberculosis infection. CONCLUSION: This preventive consultation provides a centralized and systematic setting for the direct management of patients with IMID in need of vaccination, treatment of latent disease and specific advice regarding their immunomodulating treatments. |
format | Online Article Text |
id | pubmed-8665374 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86653742021-12-13 ImmunoStart: preparing patients for immunosuppression Martin, Charlotte Muls, Vinciane Brasseur, Céline Meric de Bellefon, Laurent Lam Hoai, Xuan-Lan Vanderhilst, Jeroen Delforge, Marc Di Romana, Silvana Rheumatol Adv Pract Concise Report OBJECTIVES: Patients with immune-mediated inflammatory disease (IMID) present an increased risk of infection. Here, we present the concept of a preventive consultation called ImmunoStart and the first results of its implementation in the care pathway of patients with IMID. METHODS: Relevant information about vaccination history, tuberculosis exposure and other infectious risks were collected through blood sampling, complete anamnesis, chest X-ray and Mantoux test. During the ImmunoStart consultation, vaccination schedules, specific treatments and risk considerations were discussed. RESULTS: Between October 2016 and February 2020, 437 patients were seen at an ImmunoStart consultation, mainly referred by rheumatologists (56%), dermatologists (25%) and gastroenterologists (18%). A total of 421 (96%) patients needed at least one vaccine (a mean of 3.3 vaccines per patient). Live attenuated vaccine was indicated for 45 patients (10%), requiring them to reduce or interrupt their immunosuppressive drug(s). Ninety-two patients (21%) were treated for latent tuberculosis infection. CONCLUSION: This preventive consultation provides a centralized and systematic setting for the direct management of patients with IMID in need of vaccination, treatment of latent disease and specific advice regarding their immunomodulating treatments. Oxford University Press 2021-11-27 /pmc/articles/PMC8665374/ /pubmed/34909567 http://dx.doi.org/10.1093/rap/rkab092 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Concise Report Martin, Charlotte Muls, Vinciane Brasseur, Céline Meric de Bellefon, Laurent Lam Hoai, Xuan-Lan Vanderhilst, Jeroen Delforge, Marc Di Romana, Silvana ImmunoStart: preparing patients for immunosuppression |
title | ImmunoStart: preparing patients for immunosuppression |
title_full | ImmunoStart: preparing patients for immunosuppression |
title_fullStr | ImmunoStart: preparing patients for immunosuppression |
title_full_unstemmed | ImmunoStart: preparing patients for immunosuppression |
title_short | ImmunoStart: preparing patients for immunosuppression |
title_sort | immunostart: preparing patients for immunosuppression |
topic | Concise Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665374/ https://www.ncbi.nlm.nih.gov/pubmed/34909567 http://dx.doi.org/10.1093/rap/rkab092 |
work_keys_str_mv | AT martincharlotte immunostartpreparingpatientsforimmunosuppression AT mulsvinciane immunostartpreparingpatientsforimmunosuppression AT brasseurceline immunostartpreparingpatientsforimmunosuppression AT mericdebellefonlaurent immunostartpreparingpatientsforimmunosuppression AT lamhoaixuanlan immunostartpreparingpatientsforimmunosuppression AT vanderhilstjeroen immunostartpreparingpatientsforimmunosuppression AT delforgemarc immunostartpreparingpatientsforimmunosuppression AT diromanasilvana immunostartpreparingpatientsforimmunosuppression |